प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Elicio ने mKRAS PDAC में ELI-002 7P + nivolumab के बाद 100% CR (पूर्ण अनुक्रिया) की रिपोर्ट दी
Three patients who progressed on ELI-002 7P in Phase 2 AMPLIFY-7P achieved confirmed complete radiographic and metabolic responses after subsequent nivolumab-based therapy, with two responses lasting ≥8 months and one ongoing at >13 months. All three were MSS/MMR-p, a population historically unresponsive to checkpoint inhibitors. The company plans a Phase 1 study of ELI-002 7P + gemcitabine/nab-paclitaxel + anti-PD-1 in first-line metastatic mKRAS PDAC, subject to funding, to confirm these observations and inform future Phase 3 design.
मुख्य तथ्य
- फाइल किया गया
- 17 जून 2026, 12:03 pm
- घटना
- टॉपलाइन परिणाम
- दिशा
- सकारात्मक
- कंपनी
ELTXElicio- संपत्ति
- ELI-002 7P
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- R1 असंतुलन
- 19% बनाम 10%
- post-hoc p (R0)
- 0.048
- r0 आबादी
- 84%
- post-hoc HR (R0)
- 0.65
- post-hoc mDFS (R0)
- 23.8 महीने बनाम 12.8 महीने
- प्रतिरक्षा प्रतिक्रिया p
- <0.0001
- प्रतिरक्षा प्रतिक्रिया HR
- 0.22
स्रोत का अंश
EX-99.1 2 a2026-06x17xxeltxxxmulti.htm EX-99.1 a2026-06x17xxeltxxxmulti Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer • 100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy • Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor- based regimens • ELI-002 7P-induced mutant KRAS(“mKRAS”)-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type
इस संपत्ति पर और
उल्लेखनीय
13 अग॰ 2026
08:06 pm
ELTXElicioElicio Q4 2026 में mPDAC में Phase 1 ELI-002 7P कॉम्बो अध्ययन शुरू करेगा
उल्लेखनीय
24 जून 2026
08:05 pm
ELTXElicioELI-002 7P: mKRAS PDAC में nivolumab के बाद 3 में से 3 मरीजों में पूर्ण प्रतिक्रिया